Phase II Trial of Sorafenib in Advanced Thyroid Cancer

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

2004 • 3,873 citations

Optimal two-stage designs for phase II clinical trials

1989 • 3,494 citations

A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

2003 • 2,723 citations

BRAF mutation in thyroid cancer

2005 • 1,260 citations

BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer

2005 • 956 citations

BRAF Mutation in Papillary Thyroid Carcinoma

2003 • 915 citations

Thyroid carcinoma

2003 • 864 citations

Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning

2006 • 564 citations

Clinical Implication of Hot SpotBRAFMutation, V599E, in Papillary Thyroid Cancers

2003 • 539 citations

A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma

1985 • 458 citations

Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors

2006 • 389 citations

Distant Metastases in Differentiated Thyroid Carcinoma: A Multivariate Analysis of Prognostic Variables*

1988 • 384 citations

Prognostic Indicators of Outcomes in Patients with Distant Metastases from Differentiated Thyroid Carcinoma

2003 • 281 citations

RET/PTC Rearrangements and BRAF Mutations in Thyroid Tumorigenesis

2006 • 236 citations

Chemotherapy of Thyroid Cancer with Adriamycin

1974 • 235 citations

Mutations of the BRAF Gene in Papillary Thyroid Carcinoma in a Korean Population

2004 • 229 citations

Inhibition of Tumor Endothelial ERK Activation, Angiogenesis, and Tumor Growth by Sorafenib (BAY43-9006)

2006 • 151 citations

Prevalence of RET/PTC Rearrangements in Hashimoto's Thyroiditis and Papillary Thyroid Carcinomas

2002 • 134 citations

High Frequency of Submicroscopic Hemizygous Deletion Is a Major Mechanism of Loss of Expression ofPTENin Uveal Melanoma

2005 • 117 citations

Preliminary antitumor activity of BAY 43–9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT)

2004 • 111 citations

Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial

2007 • 93 citations

Serum Vascular Endothelial Growth Factor Levels Are Elevated in Metastatic Differentiated Thyroid Cancer but Not Increased by Short-Term TSH Stimulation

2002 • 86 citations

Predictors of Prophylactic Bilateral Salpingo-Oophorectomy Compared With Gynecologic Screening Use in BRCA1/2 Mutation Carriers

2007 • 76 citations

Vascular Endothelial Growth Factor Monoclonal Antibody Inhibits Growth of Anaplastic Thyroid Cancer Xenografts in Nude Mice

2002 • 70 citations

Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients

1999 • 67 citations

Angiogenesis inhibitors in the treatment of lung cancer

2007 • 47 citations

Preliminary antitumor activity of BAY 43–9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT)

2004 • 46 citations

Significant clinical and biologic activity of RAF/VEGF-R kinase inhibitor BAY 43–9006 in patients with metastatic papillary thyroid carcinoma (PTC): Updated results of a phase II study

2006 • 30 citations

A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers

2007 • 25 citations

Initial results from a phase II trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC)

2007 • 19 citations

Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma

2007 • 17 citations

Cited By (0)

Loading...